-
Mashup Score: 8
Disclosures. Abedin:AbbVie, Daichii Sankyo, Servier: Consultancy, Honoraria; Actinium Pharmaceutical, AltruBio, Incyte: Research Funding. Al Malki:Tr1X: Co
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMTÂ CTNÂ 0402 and 1202 - 2 month(s) ago
Key PointsPTCy uniquely alters vascular biomarkers, with an increase in Ang-2 and a decrease in EGF at day +28 after transplant.Tac/Sir regimen also alters
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
@ASamerAlHomsi1 @MGooptu @hamiltkyb #PTCy increases Ang2 and decreases EGF. Possible relationship to toxicity profile? https://t.co/cNBSmnWY4Z
-
-
Mashup Score: 1Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies - 2 year(s) ago
In search of an ideal partner or alternative to conventional immunosuppressive agents, rabbit anti-thymocyte globulin (ATG) and, more recently, post-tâŠ
Source: www.sciencedirect.comCategories: Hematologists1, Latest HeadlinesTweet-
Happy to share our comprehensive review on the combination of PT-Cy and ATG for GVHD prophylaxis in hematological malignancies. Cc @Mohty_EBMT #BloodReviews #GVHD #BMTsm #PTCy https://t.co/3UYdTUbNj6
-
-
Mashup Score: 6
Introduction: Graft-versus host disease (GVHD) is a major limitation to the success of allogeneic hematopoietic cell transplant (HCT). We hypothesized that the GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac) and mycophenolate mofetil (MMF) would reduce the incidence of GVHD in patients receiving a matched or single antigen mismatched HCT without an increase…
Source: medRxivCategories: Hem/Oncs, Latest HeadlinesTweet-
PRE-PRINT: Phase II Study of #Myeloablative 8/8- or 7/8-Matched Allotransplantation with #PTCy/Tac/MMF: Marked Reduction in #GVHD Risk Without Increased Relapse Risk Compared to Historical CSA/MTX⊠https://t.co/S0GRbkRtHh
-
-
Mashup Score: 0
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#PTcy plus tacrolimus and MMF should be standard #graftvsHostDisease prophylaxis in adults who receive a well-matched peripheral blood stem cell transplant after reduced intensity conditioning. Presented at @ASH_hematology conference #ASH22. https://t.co/2jCthRN7Gk #GVHD
-
-
Mashup Score: 0
Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent. We compared the outcomes with PT-Cy at 80âmg/kg to those with PT-Cy at 100âmg/kg in elderly patients undergoing haploidentical hematopoietic cell transplantation (HCT). Inclusion criteria included peripheral blood stem…
Source: NatureCategories: Hematologists1, Latest HeadlinesTweet-
Happy to share our latest work! Reducing PT-Cy total dose to 80 mg/kg is a safe and valid approach in elderly patients with hematological malignancies undergoing haploidentical PBSC transplantation. ARTICLE đ https://t.co/7DljtGQmxk Cc @Mohty_EBMT @Florent_Malard #BMTsm #PTCy https://t.co/uECW7QItl0
-
-
Mashup Score: 1
Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patientâŠ
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
âș Outcomes of 122 #Haplo HSCT with #PTCy for T cell acute lymphoblastic leukemia #ALL #Tcell âș Survival affected by disease status, being significantly better in CR1 âș Outcomes were not affected by conditioning, calling into question the need for TBI https://t.co/qN68UOY5pX
-
-
Mashup Score: 2
Haploidentical bone marrow transplantation using this approach results in excellent overall survival with minimal GVHD in patients who have not responded to immunosuppressive therapy, and can expand access to bone marrow transplantation across all populations. In clinical practice, this could now be considered a standard approach for salvage treatment of severe aplastic anaemia. Attention to…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502) #BMTsm âŠ@AmyDeZernâ© âŠ@BMTCTNâ© âŠ@aamdsifâ© #PTCy https://t.co/kNyMpiRFFQ
-
-
Mashup Score: 0Hematopoietic Cell Transplantation and Cell therapy weekly newsletter 26/05/2022- Issue #9 - 3 year(s) ago
THIS WEEK SUMMARY:Axicel real-world data in B cell LymphomaNeurofilament light chain as ICANS biomarkerMRD status pre alloHCT in CR1 vs CR2CD19/22 bicistronic CART for B ALLand many more…
Source: www.getrevue.coCategories: Hematologists1, Latest HeadlinesTweet-
Read my latest: âHematopoietic Cell Transplantation and Cell therapy weekly newsletter 26/05/2022- Issue #9â https://t.co/h6YvcI3BEK #alloHCT #CART #PTCy @BloodJournal @ASTCT_journal @bloodadvances @Haematologica
-
-
Mashup Score: 4Hematopoietic Cell Transplantation and Cell therapy weekly newsletter 19/05/2022- Issue #8 - 3 year(s) ago
THIS WEEK at a glance:HLA-DQ and its impact in alloHCTPhenotypic composition role of commercial anti-CD19 CARTFluMel vs FluTreo in alloHCTPTCy tacrolimus vs standard GVHD prophylaxis for MSD and MUD donorsAlloHCT for ALL in modern eraand many more!
Source: www.getrevue.coCategories: Hematologists1, Latest HeadlinesTweet-
Read my latest: âHematopoietic Cell Transplantation and Cell therapy weekly newsletter 19/05/2022- Issue #8â https://t.co/QzvSFR9zpu #alloHCT #CART #PTCy @BloodJournal @TheEBMT @ASTCT_journal @bloodadvances @Haematologica
-
The safety of allogeneic (donor) transplants has MASSIVELY improved recently. We recently saw >90% 1-year survival in patients 70 years+ undergoing #PTCy-based allo in @BMTCTN 1703 ( đ€©thx @sameem_abedin!). Wow: https://t.co/I6wBfqspmM